Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $5.7 million.

  • Exagen's Accumulated Expenses fell 798.12% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 798.12%. This contributed to the annual value of $6.9 million for FY2024, which is 816.62% down from last year.
  • As of Q3 2025, Exagen's Accumulated Expenses stood at $5.7 million, which was down 798.12% from $4.9 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Accumulated Expenses peaked at $7.5 million during Q4 2023, and registered a low of $4.9 million during Q2 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $6.0 million (2024), whereas its average is $6.1 million.
  • In the last 5 years, Exagen's Accumulated Expenses tumbled by 2166.72% in 2022 and then soared by 4084.53% in 2023.
  • Exagen's Accumulated Expenses (Quarter) stood at $6.8 million in 2021, then fell by 21.67% to $5.3 million in 2022, then skyrocketed by 40.85% to $7.5 million in 2023, then dropped by 8.17% to $6.9 million in 2024, then decreased by 17.81% to $5.7 million in 2025.
  • Its Accumulated Expenses was $5.7 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.9 million in Q1 2025.